Please assess the completion status of the following clinical trial:

Trial Title: 99mTc-MIBI SPECT/CT in Breast Malignancy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with histologically proven breast cancer~* Patients with locally advanced breast cancer (stages T2-4 N0-3 M0)~* Patients scheduled for neoadjuvant chemotherapy~* Patients scheduled for radical modified mastectomy~* Patients with no physical and/or psychological contraindications~* Patients with no recent nuclear medicine study using long-lived isotopes (i.e. 67Ga, 111In, 131I) within the 48 hour preceding the mammoscintigraphy~Exclusion Criteria:~* Patient with no histologically proven breast cancer~* Patients with early stage T1 breast cancer~* Patients who are not candidates for neoadjuvant chemotherapy~* Patients who are not surgical candidates~* Patients with physical and/or psychological contraindications~* Pregnant or breast feeding patients~* Patients with a recent nuclear medicine study using long-lived isotopes (i.e. 67Ga, 111In, 131I) within the 48 hour preceding the mammoscintigraphy

- Gender: FEMALE
- Minimum Age: 25 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Mammoscintigraphy with SPECT-CT optimized 99mTc-MIBI imaging (experimental arm) will be compared to conventional planar imaging. Mammoscintigraphy results before and after chemotherapy and radiation therapy, will be compared to the histopathological results after surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).